{"disease":{"id":"carcinosarcoma","name":"carcinosarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05049538","title":"Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03914612","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00954174","title":"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":637,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT00989651","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05646316","title":"Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT00977574","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":349,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03660826","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05537844","title":"Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Liz-Anne Lewsley","has_results":false},{"nct_id":"NCT07029399","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03422198","title":"Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT04214067","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03648489","title":"Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03570437","title":"Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":124,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT03395080","title":"A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Leap Therapeutics, Inc.","has_results":true},{"nct_id":"NCT01935934","title":"Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03367741","title":"Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":82,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT06639074","title":"Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03641287","title":"The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors","phase":"NA","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04919629","title":"APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05542407","title":"ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02203760","title":"Pazopanib Vs. Pazopanib Plus Gemcitabine","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT04092270","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04688749","title":"Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage","phase":"","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT05252416","title":"(VELA) Study of BLU-222 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT02983279","title":"Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT02993705","title":"Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05265793","title":"Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01168232","title":"Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05691504","title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05920798","title":"Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05147558","title":"A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03241745","title":"A Study of Nivolumab in Selected Uterine Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT03120624","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT00478426","title":"Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05229601","title":"A Study of HFB301001 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"HiFiBiO Therapeutics","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03694262","title":"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT05494580","title":"Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03206177","title":"Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of Oklahoma","has_results":true},{"nct_id":"NCT03552471","title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04458597","title":"Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.","phase":"NA","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT02364713","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03610490","title":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04513665","title":"ZW25 in Women With Endometrial Cancers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}